ReviewObesity (Silver Spring, Md.)2022
The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention.
Open access · greenAbstract readReview
In one paragraph
Review in Obesity (Silver Spring, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial.JAMA oncology · 2025Trial
- Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program.Cancer prevention research (Philadelphia, Pa.) · 2025 · on this mapTrial
- Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic.British journal of cancer · 2023Trial
- The feasibility of a telephone-based weight loss intervention in rural Ohio: A pilot study.PloS one · 2023Trial
- Blueprint for adapting the cardiac rehabilitation model for oncology patients with cardiovascular-kidney-metabolic syndrome.American journal of preventive cardiology · 2026Article
- A community based participatory research approach to evaluate barriers and facilitators for behavioral weight loss intervention implementation in a predominantly black community.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Tailored Exercise Strategies and Mortality Among Breast Cancer Survivors.JAMA network open · 2026Article
- DXA-Derived Visceral and Subcutaneous Adipose Tissue and Postmenopausal Breast Cancer Mortality.Current oncology (Toronto, Ont.) · 2026Article
- Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.Frontiers in oncology · 2026Article
- Impact of obesity on breast cancer recurrence by menopausal status and subtype: a retrospective cohort study.Breast cancer research and treatment · 2025Article
- Target trial emulation to estimate the effects of lifestyle interventions on mortality among cancer survivors: an editorial commentary.Annals of cancer epidemiology · 2025Article
- Adult obesity treatment and prevention: A trans-agency commentary on the research landscape, gaps, and future opportunities.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2024Review
- Long-Term High-Fat Diet Limits the Protective Effect of Spontaneous Physical Activity on Mammary Carcinogenesis.International journal of molecular sciences · 2024Article
- The relation between excess adiposity and breast cancer in women: Clinical implications and management.Critical reviews in oncology/hematology · 2024Review
- Calorie restriction outperforms bariatric surgery in a murine model of obesity and triple-negative breast cancer.JCI insight · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 16 institutions in 2 countries.
Linda M DelahantyDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-1525-3559
Thomas A WaddenDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pamela J GoodwinMount Sinai Hospital/Lunenfeld Tanenbaum Research Institute, University of Toronto, Toronto, Ontario, Canada.
Catherine M AlfanoNorthwell Health Cancer Institute; and Institute of Health System Science, Feinstein Institutes for Medical Research, New York, New York, USA.
Cynthia A ThomsonDepartment of Health Promotion Sciences, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA.
Melinda L IrwinYale School of Public Health, Yale University, New Haven, Connecticut, USA.
Marian L NeuhouserDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Tracy E CraneBiobehavioral Health Sciences Division, College of Nursing, University of Arizona, Tucson, Arizona, USA.
Elizabeth FrankDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Patricia A SpearsLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Bonnie P GillisMedical Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Dawn L HershmanDivision of Medical Oncology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
Electra D PaskettDepartment of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Judith HopkinsNovant Health Cancer Institute/Southeast Clinical Oncology Research Consortium - NCI Community Oncology Research Program, Novant Health Oncology Specialists, Winston-Salem, North Carolina, USA.
Vanessa BernsteinDivision of Medical Oncology, Department of Medicine, University of British Columbia, Vancouver, Victoria, British Columbia, Canada.
Vered StearnsSidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Julia WhiteDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Clifford HudisAmerican Society of Clinical Oncology, Alexandria, Virginia, USA.
Eric P WinerDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Ann H PartridgeDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Jennifer A LigibelDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
CancerCare · USThe Ohio State University · USUniversity of Arizona · USUniversity of North Carolina at Chapel Hill · USAmerican Society of Clinical Oncology · USColumbia University Irving Medical Center · USFred Hutch Cancer Center · USHarvard University · USJohns Hopkins University · USMount Sinai Hospital · CANorthwell Health · USNovant Health · USUniversity of British Columbia · CAUniversity of Pennsylvania · USUniversity of Pittsburgh Medical Center · USYale University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MCollaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MSWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6MNCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4MSoutheast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8MNCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180819NCI NIH HHS U10CA180819NCI NIH HHS U10 CA180820NCI NIH HHS U10CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10CA180821NCI NIH HHS U10 CA180863NCI NIH HHS U10CA180863NCI NIH HHS U10 CA180868NCI NIH HHS U10CA180868NCI NIH HHS U10 CA180882NCI NIH HHS U10CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189823NCI NIH HHS UG1CA189823NCI NIH HHS UG1 CA189828NCI NIH HHS UG1CA189828NCI NIH HHS UG1 CA189850NCI NIH HHS UG1CA189850NCI NIH HHS UG1 CA189858NCI NIH HHS UG1CA189858NCI NIH HHS UG1 CA189974NCI NIH HHS UG1CA189974NCI NIH HHS UG1 CA233180NCI NIH HHS UG1CA233180NCI NIH HHS UG1 CA233184NCI NIH HHS UG1CA233184NCI NIH HHS UG1 CA233196NCI NIH HHS UG1CA233196NCI NIH HHS UG1 CA233198NCI NIH HHS UG1CA233198NCI NIH HHS UG1 CA233290NCI NIH HHS UG1CA233290NCI NIH HHS UG1 CA233328NCI NIH HHS UG1CA233328NCI NIH HHS UG1 CA233331NCI NIH HHS UG1CA233331NCI NIH HHS UG1 CA233337NCI NIH HHS UG1CA233337NCI NIH HHS UG1 CA233373NCI NIH HHS UG1CA233373
Abstract
The Breast Cancer Weight Loss (BWEL) trial is a randomized controlled trial designed to determine whether weight loss after a breast cancer diagnosis can reduce the risk of cancer recurrence in women with overweight or obesity. The BWEL trial will compare the efficacy of a telephone-based weight-loss intervention plus health education materials versus health education materials alone on invasive disease-free survival in 3,181 women with stage II or III breast cancer and BMI > 27 kg/m
Indexed as
Breast NeoplasmsFemaleHumansLife StyleNeoplasm Recurrence, LocalOverweightRandomized Controlled Trials as TopicWeight Loss
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.